Frequent Epigenetic Inactivation of DIRAS-1 and DIRAS-2 Contributes to Chemo-Resistance in Gliomas.
chromatin
glioblastoma
histone modification
lomustine
methylation
p53
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
12 Oct 2021
12 Oct 2021
Historique:
received:
25
08
2021
revised:
30
09
2021
accepted:
08
10
2021
entrez:
23
10
2021
pubmed:
24
10
2021
medline:
24
10
2021
Statut:
epublish
Résumé
We previously reported that DIRAS-3 is frequently inactivated in oligodendrogliomas due to promoter hypermethylation and loss of the chromosomal arm 1p. DIRAS-3 inactivation was associated with better overall survival. Consequently, we now investigated regulation and function of its family members DIRAS-1 and DIRAS-2. We found that DIRAS-1 was strongly downregulated in 65% and DIRAS-2 in 100% of analyzed glioma samples compared to non-neoplastic brain tissue (NNB). Moreover, a significant down-regulation of DIRAS-1 and -2 was detected in glioma data obtained from the TCGA database. Mutational analyses did not reveal any inactivating mutations in the
Identifiants
pubmed: 34680261
pii: cancers13205113
doi: 10.3390/cancers13205113
pmc: PMC8534260
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Research Commission of the Medical Faculty of the Heinrich-Heine-University Düsseldorf
ID : 9772307
Organisme : Deutsche Forschungsgemeinschaft
ID : 422188432
Organisme : Bayerisches Staatsministerium für Wissenschaft, Forschung und Kunst
ID : Bavarian Research Network ForInter
Références
Brain Pathol. 2012 Jan;22(1):17-25
pubmed: 21631628
Proc Natl Acad Sci U S A. 1999 Nov 23;96(24):13777-82
pubmed: 10570149
Nat Rev Clin Oncol. 2017 Jul;14(7):434-452
pubmed: 28031556
Brain Pathol. 2018 Sep;28(5):695-709
pubmed: 29222813
Biochem Biophys Res Commun. 2018 Oct 28;505(2):413-418
pubmed: 30266404
J Clin Oncol. 2009 Dec 10;27(35):5874-80
pubmed: 19901110
J Pineal Res. 2019 Sep;67(2):e12586
pubmed: 31077613
J Mol Cell Biol. 2014 Dec;6(6):442-57
pubmed: 25404613
Mol Ther Nucleic Acids. 2018 Sep 7;12:845-853
pubmed: 30161023
Cell Mol Immunol. 2016 Sep;13(5):658-68
pubmed: 26189368
Nat Rev Genet. 2008 Mar;9(3):179-91
pubmed: 18250624
Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10389-94
pubmed: 10973490
Neuro Oncol. 2017 Oct 1;19(10):1316-1326
pubmed: 28419303
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Nat Cell Biol. 2000 Oct;2(10):762-5
pubmed: 11025670
Cancer Res. 2013 Apr 1;73(7):2298-309
pubmed: 23436800
Onco Targets Ther. 2017 Feb 27;10:1217-1226
pubmed: 28280356
Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):9876-81
pubmed: 12107278
BMC Cancer. 2011 Jan 19;11:22
pubmed: 21244707
BMC Neurosci. 2008 Apr 28;9:42
pubmed: 18442397
Oncogene. 2020 May;39(19):3853-3866
pubmed: 32161311
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Cell. 2013 Oct 10;155(2):462-77
pubmed: 24120142
Nature. 2012 Feb 15;483(7390):479-83
pubmed: 22343889
J Neurochem. 2012 Jul;122(2):444-55
pubmed: 22564186
Cell. 1997 Oct 31;91(3):325-34
pubmed: 9363941
J Biol Chem. 2016 Mar 18;291(12):6534-45
pubmed: 26814130
Clin Epigenetics. 2017 May 10;9:50
pubmed: 28491151
Mol Cancer. 2011 Oct 11;10:128
pubmed: 21988793
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
In Vitro Cell Dev Biol Anim. 2018 Apr;54(4):295-303
pubmed: 29556894
Neuropsychopharmacology. 2011 Oct;36(11):2318-27
pubmed: 21750579
J Gastroenterol Hepatol. 2012 Aug;27(8):1395-404
pubmed: 22497484
Pathologe. 2015 Mar;36(2):171-80
pubmed: 25820444
Cell Death Dis. 2015 Aug 06;6:e1836
pubmed: 26247722
BMC Cancer. 2019 May 14;19(1):441
pubmed: 31088402
J Biol Chem. 2002 Oct 25;277(43):41070-8
pubmed: 12194967
J Biol Chem. 2015 Aug 14;290(33):20245-56
pubmed: 26149690
Autophagy. 2018;14(4):637-653
pubmed: 29368982
Med Oncol. 2014 Mar;31(3):846
pubmed: 24458808
Int J Cancer. 2008 Jun 1;122(11):2503-10
pubmed: 18302158